Affichage 1 à 8 des 8 essais cliniques
ESSAI CLINIQUE
    No essai
    ClinicalTrials.gov ID
Investigateur(trice) principal(e)
Coordonnateur(rice)
(EN) A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
    LOXO-IDH-20001
    NCT04603001
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Leucémie myéloïde aiguë (LMA)
Syndrome myélodysplasique
Dre Sarit Assouline

(EN) A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)
    CPI-0610-02
    NCT02158858
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Syndrome myélodysplasique Dre Shireen Sirhan

Chadi Zakaria
514-340-8222 poste 28326
(EN) A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
    CR107947
    NCT02598661
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Syndrome myélodysplasique Dre April Shamy

Erika Thibault
514-340-8222
(EN) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions
    ACE-536-MDS-002
    NCT03682536
     Actif en recrutement
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX  

Syndrome myélodysplasique Dr Lambert Busque

Julie Trinh Lu
514-252-3400 poste 3336
Registre Canadien de la SMD
    Registre SMD
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS  

Syndrome myélodysplasique Dr Robert Delage

Linda Vallée
418-649-0252 poste 66602
Registre de l’hémoglobinurie paroxystique nocturne (HPN)
    Registre PNH (M07-001)
    NCT01374360
     Actif en recrutement
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX  

Syndrome myélodysplasique Dr Thomas KIss

Johanne Blais
514-252-3400 poste 3295
(EN) A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome
    Verona (M15-954)
    NCT04401748
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS  

Syndrome myélodysplasique Dr Robert Delage

Philippe Nadeau
418-649-0252 poste 63501
(EN) A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
    CMBG453B12301
    NCT04266301
     Actif en recrutement
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL  
Syndrome myélodysplasique Dr Harold J. Olney

Sonia Camara
514-890-8444